Literature DB >> 3711675

Pharmacokinetics of murine tumor necrosis factor.

D A Flick, G E Gifford.   

Abstract

The in vivo administration of tumor necrosis factor (TNF) provides a new approach to the immunotherapeutic treatment of tumors. We evaluated the pharmacokinetics of murine tumor necrosis factor in mice as a model for application in the human system. TNF had a clearance of 0.013 ml/min/g and a serum half life of 10.5 minutes. Its volume of distribution was consistent with the extracellular space. This information can provide parameters by which to select optimal modes of treatment for eradication of in vivo neoplasms.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3711675     DOI： 10.3109/08923978609031087

Source DB:  PubMed          Journal:  J Immunopharmacol        ISSN： 0163-0571


  18 in total

1.  Tumor necrosis factor enhances the sleep-like state and electrical stimulation induces a wake-like state in co-cultures of neurons and glia.

Authors:  Kathryn A Jewett; Ping Taishi; Parijat Sengupta; Sandip Roy; Christopher J Davis; James M Krueger
Journal:  Eur J Neurosci       Date:  2015-06-28       Impact factor: 3.386

2.  Protection of mice against Listeria monocytogenes infection by recombinant human tumor necrosis factor alpha.

Authors:  J V Desiderio; P A Kiener; P F Lin; G A Warr
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

3.  Development of partial tolerance to the gastrointestinal effects of high doses of recombinant tumor necrosis factor-alpha in rodents.

Authors:  J S Patton; P M Peters; J McCabe; D Crase; S Hansen; A B Chen; D Liggitt
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

4.  Serum and urine levels of tumour necrosis factor in patients with genitourinary cancer and their relevance to disease status.

Authors:  A Akdaş; L Türkeri; T Akoğlu
Journal:  Int Urol Nephrol       Date:  1990       Impact factor: 2.370

Review 5.  Are cytokines possible mediators of cancer cachexia?

Authors:  Y Noguchi; T Yoshikawa; A Matsumoto; G Svaninger; J Gelin
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

6.  Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo.

Authors:  Janice M Zabolotny; Young-Bum Kim; Laura A Welsh; Erin E Kershaw; Benjamin G Neel; Barbara B Kahn
Journal:  J Biol Chem       Date:  2008-02-14       Impact factor: 5.157

7.  Enhancement of the synthetic ligand-mediated function of liver NK1.1Ag+ T cells in mice by interleukin-12 pretreatment.

Authors:  Yoshiko Habu; Takefumi Uchida; Takuo Inui; Hiroyuki Nakashima; Masashi Fukasawa; Shuhji Seki
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

Review 8.  Interleukins. Clinical pharmacokinetics and practical implications.

Authors:  V Bocci
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

9.  Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I.

Authors:  M A Spruit; R Gosselink; T Troosters; A Kasran; G Gayan-Ramirez; P Bogaerts; R Bouillon; M Decramer
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

10.  Soluble IL-2 receptor and tumour necrosis factor-alpha in plasma of haemophilia patients infected with HIV.

Authors:  I L Noronha; V Daniel; K Schimpf; G Opelz
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.